Recently, Insilico Medicine, an AI-driven drug discovery company, announced a strategic collaboration with Qilu Pharmaceutical, a leading Chinese pharmaceutical enterprise. The partnership will leverage Insilico’s cutting-edge generative artificial intelligence and target discovery capabilities alongside Qilu’s extensive expertise in drug development, clinical trials, and commercialization to jointly advance multiple innovative drug programs. The collaboration focuses on therapeutic areas with significant unmet medical needs, including oncology and autoimmune diseases, aiming to accelerate the entire drug discovery pipeline—from target identification to clinical candidate selection. Insilico’s proprietary Pharma.AI platform has already facilitated the progression of several novel drugs into clinical trials, while Qilu brings robust manufacturing capabilities and a broad market distribution network. This alliance not only underscores the deep integration of AI into biopharmaceutical innovation but also highlights how domestic Chinese pharmaceutical companies are actively embracing advanced technologies to reshape the paradigm of drug discovery. Industry experts believe this partnership has the potential to significantly shorten drug development timelines, reduce R&D costs, and deliver more effective and precise therapies to patients.
近日，人工智能驱动的药物研发公司英矽智能（Insilico Medicine）与国内大型制药企业齐鲁制药宣布达成战略合作。双方将结合英矽智能在生成式人工智能和靶点发现领域的领先技术，以及齐鲁制药在药物开发、临床试验和商业化方面的强大能力，共同推进多个创新药物项目的研发。此次合作聚焦于肿瘤、自身免疫疾病等重大未满足临床需求的治疗领域，旨在加速从靶点识别到临床候选化合物的全流程开发。英矽智能自主研发的Pharma.AI平台已成功助力多个新药进入临床阶段，而齐鲁制药则拥有丰富的药品生产经验和广泛的市场渠道。此次强强联合，不仅体现了AI技术在生物医药领域的深度应用，也标志着中国本土药企正积极拥抱前沿科技，推动创新药研发范式的变革。业内专家认为，该合作有望显著缩短新药研发周期、降低研发成本，并为患者带来更高效、精准的治疗选择。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/22564.html